Treatment of paradoxical eczematous eruption in psoriasis treated with secukinumab: A case report.
Medicine (Baltimore)
; 102(6): e32844, 2023 Feb 10.
Article
in En
| MEDLINE
| ID: mdl-36820537
ABSTRACT
RATIONALE Eczematous eruption is an increasingly recognized form of drug-related eruption, typically reported in association with interleukin 17 (IL-17)A inhibitors. However, severe paradoxical eczematous eruption due to IL-17A inhibitors has been rarely reported. Herein, we reported a case of a man with severe psoriasis with erythematous scaly plaques on the scalp, trunk, and arms and legs after the administration of secukinumab was initiated. PATIENT CONCERNS We reported a case of a 20-year-old man with severe psoriasis with erythematous scaly plaques on the scalp, trunk, and arms and legs after the administration of secukinumab was initiated. A skin biopsy was performed. It revealed spongiotic dermatitis consistent with eczematous reaction. Direct and indirect immunofluorescence assays were negative. DIAGNOSES He was diagnosed with eczematous eruption. INTERVENTIONS:
Discontinuation of secukinumab and administration of cyclosporine and prednisone were considered.OUTCOMES:
Significant improvement was observed, with no adverse events.CONCLUSION:
Our case shows that eczematous eruption can paradoxically occur in patients on IL-17A inhibitors and this report is expected to increase awareness of the rising number of cutaneous eruptions related to biological agents.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Psoriasis
/
Drug Eruptions
/
Eczema
/
Exanthema
Type of study:
Etiology_studies
Limits:
Adult
/
Humans
/
Male
Language:
En
Journal:
Medicine (Baltimore)
Year:
2023
Type:
Article
Affiliation country:
China